Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: Report of a cooperative clinical trial

摘要: Sixty-three patients completed a multicenter 10 week, double-blind, parallel group protocol evaluating the efficacy of diltiazem versus placebo with respect to rate attacks angina, nitroglycerin consumption and duration treadmill exercise. An additional 36 were evaluated for drug safety. A 4 week lead-in phase was followed by 2 dose titration period two treatment evaluation periods weeks each. Both associated significant reduction in weekly frequency angina from baseline rate. Intergroup comparison disclosed significantly greater receiving than those placebo. similar noted consumption. Total exercise at statistically treated diltiazem. Diltiazem well tolerated. No abnormalities hematologic profiles or routine serum chemistry values observed; electrocardiographic P-R QRS intervals unaffected. Adverse effects that could have been related administration reported 11 who received 12 Of 17 episodes only 3 considered drug-related, one these resulted discontinuation drug.